Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILIST pilot: infliximab dose adjustment in IBD remission based on trough levels
2013-002651-15Phase 4Active
- Sponsor
- ZonMw
- Start
- Sep 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of infliximab in Crohn's disease and inflammatory bowel disease (IBD), sponsored by ZonMw. Primary endpoint: Number of patients in which dose could be reduced. Started Sep 2013; status: active.
02
Drugs
infliximab
03
Conditions
Crohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2013-002651-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002651-15.